Diaceutics（7DC）株式概要Diaceutics PLCは診断薬の商業化企業で、世界中の製薬会社にデータ、データ分析、導入サービスを提供している。 詳細7DC ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長5/6過去の実績0/6財務の健全性4/6配当金0/6報酬当社が推定した公正価値より0.4%で取引されている 収益は年間88.17%増加すると予測されています アナリストらは、株価が32.5%上昇するだろうとほぼ一致している。 リスク分析リスクチェックの結果、7DC 、リスクは検出されなかった。すべてのリスクチェックを見る7DC Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€1.9748.3% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-3m87m2016201920222025202620282031Revenue UK£87.1mEarnings UK£11.1mAdvancedSet Fair ValueView all narrativesDiaceutics PLC 競合他社GerresheimerSymbol: XTRA:GXIMarket cap: €943.6mEvotecSymbol: XTRA:EVTMarket cap: €929.6mPExASymbol: DB:FA0Market cap: €27.9mSCHOTT Pharma KGaASymbol: XTRA:1SXPMarket cap: €2.6b価格と性能株価の高値、安値、推移の概要Diaceutics過去の株価現在の株価UK£1.9752週高値UK£2.0252週安値UK£1.24ベータ0.921ヶ月の変化-2.48%3ヶ月変化18.67%1年変化23.13%3年間の変化111.83%5年間の変化32.21%IPOからの変化70.64%最新ニュースBoard Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 5 non-independent directors. Senior Independent Director Graham Paterson was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jan 28Diaceutics PLC to Report Fiscal Year 2025 Results on May 27, 2026Diaceutics PLC announced that they will report fiscal year 2025 results at 8:00 AM, GMT Standard Time on May 27, 2026お知らせ • Jan 15Diaceutics PLC Provides Earnings Guidance for the Year Ended December 31, 2025 and Fiscal Year 2026Diaceutics PLC provided earnings guidance for the year ended December 31, 2025 and fiscal year 2026. For the year ended December 31, 2025, reported revenues are expected to be £38.5 million (FY 2024: £32.2 million), representing growth of 20% in the year. For the year 2026, the company expects to deliver 25% revenue growth.お知らせ • Aug 05Diaceutics PLC to Report Q2, 2025 Results on Sep 15, 2025Diaceutics PLC announced that they will report Q2, 2025 results on Sep 15, 2025お知らせ • Jul 31Diaceutics PLC Appoints Lauren Dewitt as Executive Vice President, Legal, General Counsel, and Group Company SecretaryDiaceutics PLC announced the appointment of Lauren DeWitt as Executive Vice President, Legal, General Counsel, and Group Company Secretary. She will be based at the company's U.S. headquarters. Lauren brings extensive legal and leadership experience in the pharmaceutical sector. Most recently, she served as Vice President and Head of General Legal at Sandoz, where she led a team of senior attorneys supporting all facets of the U.S. business, including commercial, regulatory, quality, medical affairs, and compliance. Earlier in her career, Lauren held several key legal roles at both Sandoz and Novartis, including Global Head of Legal BD&L for Novartis Group, where she oversaw complex global transactions and strategic partnerships. She began her legal career as a litigator, representing healthcare and life sciences companies in product liability and general litigation matters.お知らせ • May 22Diaceutics PLC, Annual General Meeting, Jun 18, 2025Diaceutics PLC, Annual General Meeting, Jun 18, 2025. Location: first floor, building two, dataworks at kings hall health and wellbeing park, county antrim bt9 6gw, belfast United Kingdom最新情報をもっと見るRecent updatesBoard Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 5 non-independent directors. Senior Independent Director Graham Paterson was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jan 28Diaceutics PLC to Report Fiscal Year 2025 Results on May 27, 2026Diaceutics PLC announced that they will report fiscal year 2025 results at 8:00 AM, GMT Standard Time on May 27, 2026お知らせ • Jan 15Diaceutics PLC Provides Earnings Guidance for the Year Ended December 31, 2025 and Fiscal Year 2026Diaceutics PLC provided earnings guidance for the year ended December 31, 2025 and fiscal year 2026. For the year ended December 31, 2025, reported revenues are expected to be £38.5 million (FY 2024: £32.2 million), representing growth of 20% in the year. For the year 2026, the company expects to deliver 25% revenue growth.お知らせ • Aug 05Diaceutics PLC to Report Q2, 2025 Results on Sep 15, 2025Diaceutics PLC announced that they will report Q2, 2025 results on Sep 15, 2025お知らせ • Jul 31Diaceutics PLC Appoints Lauren Dewitt as Executive Vice President, Legal, General Counsel, and Group Company SecretaryDiaceutics PLC announced the appointment of Lauren DeWitt as Executive Vice President, Legal, General Counsel, and Group Company Secretary. She will be based at the company's U.S. headquarters. Lauren brings extensive legal and leadership experience in the pharmaceutical sector. Most recently, she served as Vice President and Head of General Legal at Sandoz, where she led a team of senior attorneys supporting all facets of the U.S. business, including commercial, regulatory, quality, medical affairs, and compliance. Earlier in her career, Lauren held several key legal roles at both Sandoz and Novartis, including Global Head of Legal BD&L for Novartis Group, where she oversaw complex global transactions and strategic partnerships. She began her legal career as a litigator, representing healthcare and life sciences companies in product liability and general litigation matters.お知らせ • May 22Diaceutics PLC, Annual General Meeting, Jun 18, 2025Diaceutics PLC, Annual General Meeting, Jun 18, 2025. Location: first floor, building two, dataworks at kings hall health and wellbeing park, county antrim bt9 6gw, belfast United Kingdomお知らせ • Apr 29Diaceutics PLC to Report Fiscal Year 2024 Final Results on May 13, 2025Diaceutics PLC announced that they will report fiscal year 2024 final results at 8:00 AM, GMT Standard Time on May 13, 2025お知らせ • Jan 28Diaceutics PLC Announces Remuneration Committee Chair Changes, Effective 1 May 2025Diaceutics PLC announced that Graham Paterson, Senior Independent Director, will, effective 1 May 2025, step down as Chair of the Remuneration Committee (but will remain a member of the Remuneration Committee) and Cheryl MacDiarmid will become Chair of the Remuneration Committee at that time. Cheryl MacDiarmid joined the Company Board as a Non-Executive Director in October 2024 and is a Non-Executive Director and serves as Remuneration Committee Chair at Allergy Therapeutics PLC.Buy Or Sell Opportunity • Oct 30Now 20% overvaluedOver the last 90 days, the stock has fallen 6.0% to €1.40. The fair value is estimated to be €1.16, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 29% in a year. Earnings are forecast to grow by 87% in the next year.お知らせ • Oct 15Diaceutics PLC Announces the Appointment of Sandra Blake as Chief People OfficerDiaceutics PLC announced the appointment of Sandra Blake as Chief People Officer. Sandra has over 25 years leadership experience across Human Resources, Marketing & Innovation in the Technology, Engineering, Banking, Insurance, FMCG, Retail and Energy sectors. Sandra has worked with companies including NatWest Group PLC, Tesco PLC, Cadbury PLC and Kraft Foods Inc.Board Change • Oct 02Less than half of directors are independentFollowing Founder & Executive Chairman Peter Keeling's arrival on 01 October 2024, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Graham Paterson was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Oct 01Diaceutics plc Announces Board ChangesDiaceutics PLC announces the following changes to its board of directors. Jordan Clark (Chief Data Officer of Diaceutics) will join the Board as an Executive Director effective 1 October 2024. Cheryl MacDiarmid will join the Board as a Non-Executive Director subject to the completion of usual Nominated Adviser due diligence checks and a further announcement will be made in due course. Having been on the Board since March 2019, Mike Wort is stepping down as a Non-Executive Director effective 1 October 2024. Graham Paterson who is currently a Non-Executive Director of Diaceutics will assume the role of Senior Independent Director effective 1 October, 2024. In addition, further to the 23 July 2024 announcement, Diaceutics confirms that Deborah Davis has stepped down from the Board with effect from 1 October 2024 and Peter Keeling has succeeded Deborah as Non-Executive Chair. Cheryl MacDiarmid has over 30 years' experience in the global pharmaceutical sector, notably with GSK, ViiV Healthcare and currently as a Non-Executive Director of AIM-listed Allergy Therapeutics. Cheryl is an internationally recognised opinion leader in the development & commercialisation of medicines. Trained as a pharmacist, she has held numerous senior leadership positions in the UK, EU, US and Canada, with responsibilities including global commercial strategy, P&L, sales, marketing, operations and Board membership. Cheryl is passionate about bringing new therapies to the right patients who can benefit. Jordan Clark is Chief Data Officer at Diaceutics. Jordan spearheads Diaceutics' comprehensive data strategy, spanning acquisition engineering and data science, to deliver cutting-edge analytics to clients and laboratories. With over a decade of experience at Diaceutics, he has cultivated a profound understanding of the critical role real-world data plays in optimising precision medicine. Jordan's academic and professional credentials in biomedical and clinical sciences, coupled with his state licensure as a haematology scientist, underscore his expertise. Additionally, Jordan is renowned for proficiency testing, bioinformatics and biomarker testing, honed through his involvement with UK NEQAS.Reported Earnings • Sep 23First half 2024 earnings released: UK£0.031 loss per share (vs UK£0.018 loss in 1H 2023)First half 2024 results: UK£0.031 loss per share (further deteriorated from UK£0.018 loss in 1H 2023). Revenue: UK£12.3m (up 24% from 1H 2023). Net loss: UK£2.58m (loss widened 74% from 1H 2023). Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 87 percentage points per year, which is a significant difference in performance.お知らせ • Sep 09Diaceutics PLC to Report Q2, 2024 Results on Sep 17, 2024Diaceutics PLC announced that they will report Q2, 2024 results on Sep 17, 2024お知らせ • Aug 27Diaceutics PLC Launches Enhanced Rare-Disease OfferingDiaceutics PLC announced a significant enhancement to its offering which has facilitated a new rare-disease contract win. Access to this new data will revolutionise the early identification of patients, a crucial growth area for pharma companies developing therapies for rare-diseases. Leveraging data utilisation, it will improve earlier patient diagnosis and ultimately, clinical outcomes. Driving this enhancement are 3 key developments within the Diaceutics business as follows: Onboarding of New Data Partners:A number of new rare-disease genomic lab data partners have joined the DXRX network. These partners specialise in genetic testing, including the recognised testing lab in the United States for genetically acquired rare diseases. Advanced Lab Labelling Natural Language Processing (NLP):Diaceutics has updated its advanced lab labelling NLP process to standardise and add value to the new data. This process enables complex labelling such as pathogenic vs Variants of Unknown Significance (VUS) variant calling which until now has proven challenging for the industry to identify. Access to Additional Industry Experts:The company now has a team of industry experts with deep rare-disease experience to support biopharma business opportunities and ensure clients derive maximum value from Diaceutics' deep-data offering. Despite medical and scientific advances, diagnosing rare diseases remains a significant challenge for biopharma companies. Many patients face years of multiple referrals, inconclusive test results and limited treatment benefits. Early diagnosis and quick interventions are crucial for patient survival and quality of life. A precision medicine approach can end these diagnostic odysseys and open opportunities for better clinical outcomes for patients in need. The strategic enhancements announced will enable Diaceutics to identify more patients earlier and in doing so, help pharma customers to better commercialise gene therapies for rare diseases. Leveraging these business enhancements, Diaceutics has already secured a new contract to provide a multi-product solution to support the commercialisation of a therapy in a rare autosomal-recessive disease. This initial contract win demonstrates Diaceutics' ability to meet the complex needs of this market.お知らせ • Aug 19Diaceutics PLC Announces Launch of PMxDiaceutics announced it has launched PMx, a suite of data-driven services built for the promotion and commercialisation of precision medicines and that it has reached agreement with a leading biotech to become its primary promotional partner for the launch of a breakthrough oncology precision medicine in the US using PMx. This partnership represents Diaceutics' seventh enterprise-wide engagement, and the first PMx primary promotional partnership deal whereby Diaceutics' fee structure is aligned with patient recruitment onto therapy. PMx unlocks new revenue streams for Diaceutics and shows the path to considerable increase in revenue per brand. Terms of the Agreement: Under the terms of the agreement, Diaceutics will leverage its DxRx platform, specifically its best-in-class genomic lab data, lab network, omni-channel, digital and peer to peer physician education to enable drug commercialisation. Diaceutics' partner will retain all rights to the license for the drug. This agreement is to deploy PMx through to the end of 2025 and is worth at least £2.4 million in service revenue to Diaceutics, with additional milestone fees estimated to be worth another £1.9 million payable during that period based on successful patient recruitment onto therapy. There is an expectation that the agreement will extend beyond 2025 should the initial phase be successful.お知らせ • Jul 23Diaceutics plc Announces Board ChangesDiaceutics PLC announces the following changes to its board. Deborah Davis has informed the board after three and a half years' service as Non-Executive Chair of Diaceutics, of her intention to step down from the board effective 1 October 2024. Peter Keeling, a co-founder and Executive Director of Diaceutics will succeed Deborah as Non-Executive Chair effective 1 October 2024. Peter will also serve as a Non-Executive Director on the Remuneration and Audit & Risk Committees.Recent Insider Transactions • May 26Independent Non-Executive Director recently bought €60k worth of stockOn the 22nd of May, Graham Paterson bought around 40k shares on-market at roughly €1.51 per share. This transaction increased Graham's direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €123k more in shares than they have sold in the last 12 months.Reported Earnings • May 22Full year 2023 earnings releasedFull year 2023 results: Revenue: UK£23.7m (up 22% from FY 2022). Net loss: UK£1.75m (down 341% from profit in FY 2022). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.お知らせ • Mar 21Diaceutics PLC Launches Significant Upgrade to Its DXRX PlatformDiaceutics PLC has launched a significant upgrade to its DXRX platform, including industry and technologically leading de-identification, generative AI (Diaceutics Large Lab Model, DLLM) and new comprehensive US data sets that include data on social determinants of health. Not only does the upgrade increase the power and efficiency of the platform, but also the applicability of Diaceutics' subscription services into new parts of the precision medicine lifecycle, expanding the Company's addressable market. This new functionality enables the DXRX platform to breakdown siloed datasets and provide greater depth and breadth of Diaceutics' longitudinal insight of the patient journey, at increased speed and scale. As a result of the upgrade, multiple stakeholders within the life sciences industry can now access a best in class, real world data set that is HIPAA compliant, at a pace that previously would not have been possible, helping to address healthcare inequalities and enable more patients to access appropriate therapies.お知らせ • Jan 19+ 1 more updateDiaceutics PLC, Annual General Meeting, Jun 24, 2024Diaceutics PLC, Annual General Meeting, Jun 24, 2024.New Risk • Oct 10New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €92.7m (US$98.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (0.03% net profit margin). Market cap is less than US$100m (€92.7m market cap, or US$98.0m).Board Change • Oct 05Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Chair Llewelyn Davis was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Sep 28First half 2023 earnings released: UK£0.018 loss per share (vs UK£0.009 loss in 1H 2022)First half 2023 results: UK£0.018 loss per share (further deteriorated from UK£0.009 loss in 1H 2022). Revenue: UK£9.92m (up 32% from 1H 2022). Net loss: UK£1.49m (loss widened 94% from 1H 2022). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 50 percentage points per year, which is a significant difference in performance.New Risk • Sep 27New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 0.03% Last year net profit margin: 0.8% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. This is currently the only risk that has been identified for the company.お知らせ • Sep 27Diaceutics Announces Executive ChangesDiaceutics announced the founder and chief executive of the company is stepping down after nearly two decades at the helm. Peter Keeling co-founded the company in 2005, growing it from a small consulting service provider to a listed company which employs 161 people across Europe and North America. He will step down as chief executive in January, with chief information officer Ryan Keeling becoming chief executive-designate with immediate effect. Ryan, who is Peter’s nephew, joined Diaceutics in 2006 and became a member of the board of directors following the company's listing on the AIM in 2019.お知らせ • Sep 22Diaceutics PLC Announces Executive Changes, Effective 1 October 2023Diaceutics PLC announced the appointment of Graham Paterson as an independent Non-Executive Director of the company effective 1 October 2023. The Company also announced the retirement of Charles Hindson as a Non-Executive Director of Diaceutics PLC also effective 1 October 2023. Graham Paterson is a highly experienced business leader and Non-Executive Director. He is currently a Non-Executive Director of Invesco Perpetual UK Smaller Companies Investment Trust plc, Baillie Gifford US Growth Trust plc and Chairman of Mobeus Income and Growth 4 VCT plc.He has held senior executive roles in a number of companies including TopQ Software Ltd. and SL Capital Partners. Graham Paterson is a Chartered Accountant and a member of the Institute of Chartered Accountants of Scotland and holds an Honours degree in Economics and Management from the University of St. Andrews. On appointment, Graham Paterson will become Chair of the Audit and Remuneration Committees of Diaceutics PLC.お知らせ • Aug 29Diaceutics plc Launches Daily Alerts for Dxrx PlatformDiaceutics PLC announced an important and innovative upgrade to its DXRX platformwhichsees the Company's DXRX Signal productnowproviding alerts on a daily basis. This ground-breaking innovation will provide Diaceutics' customers witheven more timely data to identifypatients who would benefit from their therapies and improve their commercial success. For patients, it means their chances of receiving the optimal therapy within the window of effectiveness is significantly improved. DXRX Signal utilizes real-world data collected from a diverse network of over ~500 labs, encompassing academic, community, and commercial facilities. This comprehensive data pool ensures supply chain reliability and encompasses both geographical and clinical diversity. For Diaceutics' customers, this translates into extensive coverage across a spectrum of medical conditions, including oncology, rare diseases, auto-immune disorders, cardiovascular and infectious diseases. DXRX Signal has identified over 46,000 patients so far in 2023 for its biopharma clients. Building upon the foundation of DXRX Signal, Diaceutics has introduced this pivotal enhancement. These alerts, now available on a daily basis, empower Diaceutics' customers with even timelier insights as they deploy products to pinpoint patients and elevate their commercial success. This innovation equips healthcare professionals with crucial data on a daily basis, and within days of a positive test result. With increased timely access to diagnostic information, physicians can be engaged precisely during the treatment decision window, ensuring the most effective drugs or therapies are offered promptly to patients.お知らせ • Jul 25Diaceutics PLC to Report First Half, 2023 Results on Sep 26, 2023Diaceutics PLC announced that they will report first half, 2023 results on Sep 26, 2023Reported Earnings • Apr 19Full year 2022 earnings released: EPS: UK£0.009 (vs UK£0.007 in FY 2021)Full year 2022 results: EPS: UK£0.009 (up from UK£0.007 in FY 2021). Revenue: UK£19.5m (up 40% from FY 2021). Net income: UK£724.0k (up 29% from FY 2021). Profit margin: 3.7% (down from 4.0% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.お知らせ • Nov 01Diaceutics PLC Announces Release of Study into Inefficiencies Within Personalised Medicine and Its Impact on Cancer PatientsDiaceutics PLC announced the release of a large-scale study highlighting that a significant number of eligible patients treated for lung cancer did not receive access to the medicines most suitable to them, and therefore did not benefit from personalised medicine treatment. The study, carried out in conjunction with a broad stakeholder group across the Personalised Medicine Coalition, was made possible by the Diaceutics Data Repository, a database consisting of 600 million patient records available on the DXRX platform. The study examined de-identified Medicare claims and laboratory data from 38,068 US-based patients diagnosed with advanced non-small cell lung cancer in 2019 to identify the operational inefficiencies in the diagnosis and testing journey across this dataset. Overall, the publication identified that diagnostic testing-informed treatment strategies benefitted only 36% of the patients in the cohort. Of this group, 18% of patients did not receive the correct treatment as a result of inconclusive or false negative diagnostic results, and 29% of patients who had a successful diagnostic test were not prescribed the indicated treatment that they could have benefitted from. These findings represent the first step in understanding and pinpointing the nuances behind what prevents millions of people from getting the correct and timely healthcare they need. While the study was collected from US-based data, the findings are significant and reflective of the clinical gaps across other geographies and cancer types. For the pharmaceutical community, the study highlights the need for greater investment into those technologies and data repositories which facilitate the wider application of personalised medicines. It also provides the basis for better understanding the action required by these stakeholders to tackle these clinical gaps, and to track progress going forward. Diaceutics' Data Repository represents a world-leading diagnostic data set, combining multiple sources of information to build a complete picture of a typical patient's diagnostic journey. The mining capability of the DXRX platform allows the Company to identify Disease Diagnostic Pathways (DDPs) to determine the best possible testing journey for patients within a specific disease or disease area. The DDPs are both unique and proprietary to Diaceutics and are increasingly being developed for other therapeutic areas. As Diaceutics invests further in its platform, it will utilise access to the unrivalled wealth of data to continue removing testing hurdles and increasing patients' access to precision medicine.Reported Earnings • Sep 28First half 2022 earnings released: UK£0.009 loss per share (vs UK£0.004 loss in 1H 2021)First half 2022 results: UK£0.009 loss per share (further deteriorated from UK£0.004 loss in 1H 2021). Revenue: UK£7.53m (up 26% from 1H 2021). Net loss: UK£767.0k (loss widened 129% from 1H 2021). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.お知らせ • Jul 26Diaceutics PLC to Report First Half, 2022 Results on Sep 27, 2022Diaceutics PLC announced that they will report first half, 2022 results on Sep 27, 2022お知らせ • Jun 07Diaceutics PLC Announces New AI and ML Capabilities Enhance DXRX PlatformDiaceutics PLC has announced significant enhancements to its proprietary DXRX platform, improving the user experience. From within their DXRX dashboard, customers can now access three new AI-powered tools, helping to ensure their medicines get to patients quicker. They are Smart Trend Analysis, Next Best Step and Event Alerts. Smart Trend Analysis:provides automated analysis of key trends and changes within customer data to uncover hidden insights including the production of bespoke, meaningful commentary for use in reports, with the customer able to customise the reports to focus on the datasets important to them. Next Best Step:provides automated identification as to where in the ecosystem customers should target their diagnostics investments in order to get patients tested and treated faster. Event Alerts:deliver just in time email notifications on significant changes within the data, such as if a new lab has started to offer diagnostic testing. These services are highly sought-after by Diaceutics customers and previously relied on the expertise of the Diaceutics' data analysis team or availability of the customers' own data science resource. Now produced automatically,customer queries can be answered more comprehensively and faster than ever before. This increased functionality represents a significant step in Diaceutics' strategy to embed its platform within its customers' own digital systems and day-to-day commercial processes.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. CFO & Director Nick Roberts was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Recent Insider Transactions • Apr 10Executive Officer recently sold €237k worth of stockOn the 6th of April, Philip White sold around 200k shares on-market at roughly €1.19 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €464k more than they bought in the last 12 months.お知らせ • Dec 09Diaceutics PLC Announces Test Signal Launch and Contract WinsDiaceutics PLC announced the launch of its real-time Test Signal service in the US. Test Signal alerts a pharma customer when a patient tests positive for a biomarker linked to the profile of therapeutic linked to the pharmaceutical company. This information can now be provided within days of the test result being recorded by laboratories linked to this new service. Test Signal allows the opportunity for real time identification of patients eligible for treatment and follow up by the pharmaceutical company's marketing organisation. This will allow quicker and better support to biomarker testing, allowing earlier treatment with the most appropriate drug treatment sooner. Test Signal was previously available as a monthly report. However, with the additional investment Diaceutics' has made, Test Signal alert is now available as a real time report further enhancing the DXRX Diaceutics Commercialisation Platform. This service now adds to the comprehensive suite of modules now being offered by Diaceutics, on a subscription basis. Work is now nearing completion for additional modules that will join Test Signal on the DXRX Commercialisation Platform. Test Signal was trialled prior to launch with key Pharma clients from the beginning of November 2021 and the Company is delighted to report that it has already secured six multiyear data subscriptions for the service. This opens up a new revenue stream for Diaceutics which will be added to as the Commercialisation Platform matures, underpinning the Company's confidence in achieving sustained long-term growth.Reported Earnings • Sep 16First half 2021 earnings released: UK£0.004 loss per share (vs UK£0.015 profit in 1H 2020)The company reported a soft first half result with weaker earnings and weaker control over costs, although revenues improved. First half 2021 results: Revenue: UK£5.97m (up 13% from 1H 2020). Net loss: UK£335.0k (down 131% from profit in 1H 2020).お知らせ • Sep 15Diaceutics PLC Provides Earnings Guidance for the Year 2021Diaceutics PLC provided earnings guidance for the year 2021. This shift in the trend of seasonality is reflected in revenue result reported for first half of 2021 which represents 44% of the external revenue expectations for the 2021 financial year (H1 2020: 41% of total revenue for the 2020 financial year).Recent Insider Transactions • May 14Chief Commercial Officer recently sold €73k worth of stockOn the 12th of May, Jordan Clark sold around 50k shares on-market at roughly €1.45 per share. In the last 3 months, there was an even bigger sale from another insider worth €284k. Insiders have been net sellers, collectively disposing of €357k more than they bought in the last 12 months.Recent Insider Transactions • May 07CFO & Executive Director recently sold €284k worth of stockOn the 4th of May, Philip White sold around 200k shares on-market at roughly €1.42 per share. This was the largest sale by an insider in the last 3 months. This was Philip's only on-market trade for the last 12 months.Reported Earnings • Mar 16Full year 2020 earnings releasedThe company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: UK£12.7m (down 5.6% from FY 2019). Net income: UK£263.0k (down 34% from FY 2019). Profit margin: 2.1% (down from 3.0% in FY 2019).お知らせ • Mar 05Diaceutics PLC Appoints Nikita Lynn as Vice President of FinanceDiaceutics PLC announced the appointment of Nikita Lynn as Vice President of Finance. Nikita has been promoted to this role following her tenure as Senior Director of Corporate Advancement. In her new role within Diaceutics, Nikita will be responsible for the financial operations and corporate development of the Company, reporting to the CFO, Board of Directors and Non-Executive Directors. She brings extensive experience in financial reporting, taxation and auditing for public companies to the position.Valuation Update With 7 Day Price Move • Jan 12Investor sentiment improved over the past weekAfter last week's 18% share price gain to UK£1.89, the stock is trading at a trailing P/E ratio of 32.5x, up from the previous P/E ratio of 27.6x. This compares to an average P/E of 60x in the Life Sciences industry in Europe. Total returns to shareholders over the past year are 45%.お知らせ • Jan 11Diaceutics PLC to Report Fiscal Year 2020 Results on Mar 15, 2021Diaceutics PLC announced that they will report fiscal year 2020 results on Mar 15, 2021Valuation Update With 7 Day Price Move • Dec 28Investor sentiment improved over the past weekAfter last week's 141% share price gain to UK£3.50, the stock is trading at a trailing P/E ratio of 24.9x, up from the previous P/E ratio of 10.3x. This compares to an average P/E of 59x in the Life Sciences industry in Europe. Total returns to shareholders over the past year are 198%.お知らせ • Dec 23+ 1 more updateDiaceutics PLC Announces the Resignation of Julie Goonewardene as Non-Executive Chair, with Effect from December 31, 2020Diaceutics PLC announced the resignation of Julie Goonewardene as Non-Executive Chair. Julie will step down on December 31, 2020. Having been with Diaceutics for almost 10 years Julie has, with the support of the Board, decided to step down.お知らせ • Dec 02Diaceutics and Alva10 Partner to Deliver Value-Based Test Reimbursement Model for US Payers, Pharma and Testing Providers Via Dxrx PlatformDiaceutics PLC announced a new partnership with Alva10 to address test coverage and reimbursement challenges in precision medicine diagnostics. The partnership will leverage Diaceutics’ newly-launched platform DXRX – The Diagnostic Network to facilitate collaboration between pharma, health insurance and government payers, labs and diagnostic companies earlier in the test development process and deliver enhanced coverage and reimbursement support for biomarker testing to improve patient outcomes. The partnership sees Alva10 join the DXRX global network of leading providers in precision medicine diagnostics in 51 countries including the areas of test standardization, access and reimbursement, quality assessment, laboratory training, technical support and education, all with the shared vision of enabling the seamless delivery of diagnostic testing for precision medicines. Alva10 works with payers and physicians to identify areas of inefficient spend, where coverage of diagnostic tools can improve patient outcomes and payer economics. Through the company’s proprietary model M.A.T.E.TM, Alva10 restructures the relationship between health insurance payers and precision medicine diagnostic companies to increase utilization and compliance. This enables optimal use of diagnostic tools to improve diagnosis of disease, determine drug response, and identify adverse events. Diaceutics’ partnership with Alva10 on its DXRX platform addresses the need for a better test reimbursement model in the US, to enable collaboration earlier in the development process, so that test developers and providers are adequately resourced to develop tests for new therapies coming to market. In today’s system, the most common practice for test reimbursement involves a laboratory or diagnostic company developing the test, followed by a process to prove clinical utility and cost-effectiveness of the test. The end goal is to gain coverage and reimbursement at a level that enables market success for the test’s associated therapy.お知らせ • Oct 29Diaceutics PLC Launches Diagnostic Network for Precision Medicine to Solve Global Cancer Testing IssuesDiaceutics PLC announced the launch of DXRX – The Diagnostic Network which has been designed to accelerate the end-to-end development and commercialization of precision medicine diagnostics by reducing time to peak biomarker test adoption for cancer testing from years to months. As a solution to today’s broken testing ecosystem, DXRX brings together stakeholders from across the industry to collaborate in a vibrant marketplace to solve real-world testing issues in a secure, standardized way for patients. DXRX integrates a pipeline of global diagnostic testing data into one secure platform providing access to transparent, real-time reporting on diagnostic utilization at a local level across multiple therapeutic areas. Early collaborations between pharma, labs and diagnostic companies are live on the platform’s marketplace with 38 Laboratories and Diagnostic Companies onboarded from across EU, Asia and the US. These collaborations are designed to improve test standardization, reimbursement, regulatory support and External Quality Assessment (EQA). Collaborators include Synlab, PathGroup (US), SRL Diagnostics (Asia), Fundación Jimenez Díaz, The Royal Marsden NHS Foundation Trust, Istituto Nazionale Tumori Regina Elena Roma and Diatech Pharmacogenetics (EU). Two global pharmaceutical clients are also piloting the technology. The platform enables pharma clients to monitor and enhance test quality at local level to increase return on investment across multiple brands, and leverage a broad network of local partnership opportunities to implement best-in-class testing for their precision medicine portfolios. DXRX also enables clients to outsource the end-to-end diagnostic development and commercialization process from biomarker discovery to in-market test availability in order to reduce time to market for new therapies. Furthermore, DXRX also provides users access to a global expert advisory panel of key opinion leaders from the areas of oncology, including lung cancer research and colorectal research; pathology, including tissue pathology and uropathology; molecular diagnostics; digital image analysis; telemedicine and informatics; external quality assessment (EQA); and FDA-expertise.Valuation Update With 7 Day Price Move • Oct 29Market pulls back on stock over the past weekAfter last week's 28% share price decline to UK£1.38, the stock is trading at a trailing P/E ratio of 27.1x, down from the previous P/E ratio of 37.9x. This compares to an average P/E of 60x in the Life Sciences industry in Europe. Total returns to shareholders over the past year are 24%.お知らせ • Oct 05Diaceutics PLC Partners with Global EQA Providers to Implement Best-In-Class Testing StandardsDiaceutics PLC announces three new partnerships on its DXRX platform, as it continues with its mission to get every patient the treatment they deserve. The company has signed agreements with external quality assessment (EQA) organizations Canadian Pathology Quality Assurance – Assurance Qualité Canadienne en Pathologie (CPQA-AQCP), European Molecular Genetics Quality Network (EMQN CIC) and Nordic Immunohistochemical Quality Control (NordiQC). The partnerships will help to establish best-in-class global laboratory standards for diagnostic testing through in-lab quality assurance and will provide the transparency which pharmaceutical companies need to reach more patients with their precision medicines. By partnering with CPQA-AQCP, EMQN CIC and NordiQC on DXRX – the world’s first diagnostic network for precision medicine – Diaceutics will support the implementation of accurate and high-quality testing across its 2500+ laboratory relationships. These collaborations facilitate a critical piece of the end-to-end solution which DXRX enables for the development and commercialization of precision medicine diagnostics. They are also part of multiple partnerships which Diaceutics is building with industry providers across the globe to help achieve their mission of getting every patient the treatment they deserve. Currently focused on the Canadian market, CPQA-AQCP is dedicated to monitoring and improving the proficiency of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) testing. DXRX is a global platform which will enable CPQA-AQCP to expand its services further worldwide. The organization is currently collaborating with Diaceutics on a project sponsoring the HER2 biomarker modules for gastric cancer. Using IHC and FISH, they are assessing the landscape and efficiency of HER2 gastric cancer testing, which has now been on the market for more than 10 years. EMQN CIC provides molecular genetics, molecular pathology, and technique-specific EQA schemes for the global molecular testing market. It is currently collaborating with Diaceutics on a pilot study involving mutations in the EGFR, PIK3CA, KRAS, HRAS, NRAS, KIT, TP53 and BRAF genes, which will help laboratories using high throughput technologies – such as NGS – to accurately validate assay sensitivity and specificity.お知らせ • Aug 27Diaceutics PLC announced that it has received £4 million in funding from SVB Silicon Valley Bank, Investment ArmDiaceutics PLC (AIM:DXRX) announced that it has received £4 million in a round of funding from returning invetsor SVB Silicon Valley Bank, Investment Arm on August 26, 2020.株主還元7DCDE Life SciencesDE 市場7D0%11.9%3.2%1Y23.1%-10.8%2.5%株主還元を見る業界別リターン: 7DC過去 1 年間で-10.8 % の収益を上げたGerman Life Sciences業界を上回りました。リターン対市場: 7DC過去 1 年間で2.5 % の収益を上げたGerman市場を上回りました。価格変動Is 7DC's price volatile compared to industry and market?7DC volatility7DC Average Weekly Movement5.4%Life Sciences Industry Average Movement9.0%Market Average Movement6.1%10% most volatile stocks in DE Market13.3%10% least volatile stocks in DE Market2.7%安定した株価: 7DC 、 German市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 7DCの 週次ボラティリティ ( 5% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2005213Ryan Keelingwww.diaceutics.comDiaceutics PLCは診断薬商業化企業で、世界中の製薬会社にデータ、データ分析、導入サービスを提供している。同社は、精密医療のための診断薬商業化プラットフォームであるDXRXを提供しており、検査機関ネットワークからの診断検査データの複数のパイプラインを統合している。また、DXRXデータソリューションとして、治療決定のための検査行動に関する実用的なアラートを提供するDXRXシグナル、患者レベルのデータを使用して医師の検査行動を調査し、検査率、検査方法、医師と検査室の関係を特定するDXRX Physician Mapping、特定の疾患またはバイオマーカーで診断された患者を現在検査している検査室に関する洞察を提供するDXRX Lab Mapping、バイオマーカー検査率レポートを提供するDXRX Disease Testing Rate Trackerを提供している。さらに、マーケット・ランドスケープ、導入、コンサルティング・サービスなどのプロフェッショナル・サービスも提供している。Diaceutics PLCは2005年に設立され、英国のベルファストに本社を置いている。もっと見るDiaceutics PLC 基礎のまとめDiaceutics の収益と売上を時価総額と比較するとどうか。7DC 基礎統計学時価総額€163.23m収益（TTM）-€1.76m売上高(TTM)€39.84m4.1xP/Sレシオ-92.7xPER（株価収益率7DC は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計7DC 損益計算書（TTM）収益UK£34.40m売上原価UK£4.78m売上総利益UK£29.63mその他の費用UK£31.15m収益-UK£1.52m直近の収益報告Jun 30, 2025次回決算日May 26, 2026一株当たり利益（EPS）-0.018グロス・マージン86.12%純利益率-4.42%有利子負債／自己資本比率0%7DC の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 12:37終値2026/05/18 00:00収益2025/06/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Diaceutics PLC 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Hayley PalmerCanaccord GenuityJulie SimmondsPanmure LiberumJulie SimmondsPanmure Liberum2 その他のアナリストを表示
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 5 non-independent directors. Senior Independent Director Graham Paterson was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jan 28Diaceutics PLC to Report Fiscal Year 2025 Results on May 27, 2026Diaceutics PLC announced that they will report fiscal year 2025 results at 8:00 AM, GMT Standard Time on May 27, 2026
お知らせ • Jan 15Diaceutics PLC Provides Earnings Guidance for the Year Ended December 31, 2025 and Fiscal Year 2026Diaceutics PLC provided earnings guidance for the year ended December 31, 2025 and fiscal year 2026. For the year ended December 31, 2025, reported revenues are expected to be £38.5 million (FY 2024: £32.2 million), representing growth of 20% in the year. For the year 2026, the company expects to deliver 25% revenue growth.
お知らせ • Aug 05Diaceutics PLC to Report Q2, 2025 Results on Sep 15, 2025Diaceutics PLC announced that they will report Q2, 2025 results on Sep 15, 2025
お知らせ • Jul 31Diaceutics PLC Appoints Lauren Dewitt as Executive Vice President, Legal, General Counsel, and Group Company SecretaryDiaceutics PLC announced the appointment of Lauren DeWitt as Executive Vice President, Legal, General Counsel, and Group Company Secretary. She will be based at the company's U.S. headquarters. Lauren brings extensive legal and leadership experience in the pharmaceutical sector. Most recently, she served as Vice President and Head of General Legal at Sandoz, where she led a team of senior attorneys supporting all facets of the U.S. business, including commercial, regulatory, quality, medical affairs, and compliance. Earlier in her career, Lauren held several key legal roles at both Sandoz and Novartis, including Global Head of Legal BD&L for Novartis Group, where she oversaw complex global transactions and strategic partnerships. She began her legal career as a litigator, representing healthcare and life sciences companies in product liability and general litigation matters.
お知らせ • May 22Diaceutics PLC, Annual General Meeting, Jun 18, 2025Diaceutics PLC, Annual General Meeting, Jun 18, 2025. Location: first floor, building two, dataworks at kings hall health and wellbeing park, county antrim bt9 6gw, belfast United Kingdom
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 5 non-independent directors. Senior Independent Director Graham Paterson was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jan 28Diaceutics PLC to Report Fiscal Year 2025 Results on May 27, 2026Diaceutics PLC announced that they will report fiscal year 2025 results at 8:00 AM, GMT Standard Time on May 27, 2026
お知らせ • Jan 15Diaceutics PLC Provides Earnings Guidance for the Year Ended December 31, 2025 and Fiscal Year 2026Diaceutics PLC provided earnings guidance for the year ended December 31, 2025 and fiscal year 2026. For the year ended December 31, 2025, reported revenues are expected to be £38.5 million (FY 2024: £32.2 million), representing growth of 20% in the year. For the year 2026, the company expects to deliver 25% revenue growth.
お知らせ • Aug 05Diaceutics PLC to Report Q2, 2025 Results on Sep 15, 2025Diaceutics PLC announced that they will report Q2, 2025 results on Sep 15, 2025
お知らせ • Jul 31Diaceutics PLC Appoints Lauren Dewitt as Executive Vice President, Legal, General Counsel, and Group Company SecretaryDiaceutics PLC announced the appointment of Lauren DeWitt as Executive Vice President, Legal, General Counsel, and Group Company Secretary. She will be based at the company's U.S. headquarters. Lauren brings extensive legal and leadership experience in the pharmaceutical sector. Most recently, she served as Vice President and Head of General Legal at Sandoz, where she led a team of senior attorneys supporting all facets of the U.S. business, including commercial, regulatory, quality, medical affairs, and compliance. Earlier in her career, Lauren held several key legal roles at both Sandoz and Novartis, including Global Head of Legal BD&L for Novartis Group, where she oversaw complex global transactions and strategic partnerships. She began her legal career as a litigator, representing healthcare and life sciences companies in product liability and general litigation matters.
お知らせ • May 22Diaceutics PLC, Annual General Meeting, Jun 18, 2025Diaceutics PLC, Annual General Meeting, Jun 18, 2025. Location: first floor, building two, dataworks at kings hall health and wellbeing park, county antrim bt9 6gw, belfast United Kingdom
お知らせ • Apr 29Diaceutics PLC to Report Fiscal Year 2024 Final Results on May 13, 2025Diaceutics PLC announced that they will report fiscal year 2024 final results at 8:00 AM, GMT Standard Time on May 13, 2025
お知らせ • Jan 28Diaceutics PLC Announces Remuneration Committee Chair Changes, Effective 1 May 2025Diaceutics PLC announced that Graham Paterson, Senior Independent Director, will, effective 1 May 2025, step down as Chair of the Remuneration Committee (but will remain a member of the Remuneration Committee) and Cheryl MacDiarmid will become Chair of the Remuneration Committee at that time. Cheryl MacDiarmid joined the Company Board as a Non-Executive Director in October 2024 and is a Non-Executive Director and serves as Remuneration Committee Chair at Allergy Therapeutics PLC.
Buy Or Sell Opportunity • Oct 30Now 20% overvaluedOver the last 90 days, the stock has fallen 6.0% to €1.40. The fair value is estimated to be €1.16, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 29% in a year. Earnings are forecast to grow by 87% in the next year.
お知らせ • Oct 15Diaceutics PLC Announces the Appointment of Sandra Blake as Chief People OfficerDiaceutics PLC announced the appointment of Sandra Blake as Chief People Officer. Sandra has over 25 years leadership experience across Human Resources, Marketing & Innovation in the Technology, Engineering, Banking, Insurance, FMCG, Retail and Energy sectors. Sandra has worked with companies including NatWest Group PLC, Tesco PLC, Cadbury PLC and Kraft Foods Inc.
Board Change • Oct 02Less than half of directors are independentFollowing Founder & Executive Chairman Peter Keeling's arrival on 01 October 2024, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Graham Paterson was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 01Diaceutics plc Announces Board ChangesDiaceutics PLC announces the following changes to its board of directors. Jordan Clark (Chief Data Officer of Diaceutics) will join the Board as an Executive Director effective 1 October 2024. Cheryl MacDiarmid will join the Board as a Non-Executive Director subject to the completion of usual Nominated Adviser due diligence checks and a further announcement will be made in due course. Having been on the Board since March 2019, Mike Wort is stepping down as a Non-Executive Director effective 1 October 2024. Graham Paterson who is currently a Non-Executive Director of Diaceutics will assume the role of Senior Independent Director effective 1 October, 2024. In addition, further to the 23 July 2024 announcement, Diaceutics confirms that Deborah Davis has stepped down from the Board with effect from 1 October 2024 and Peter Keeling has succeeded Deborah as Non-Executive Chair. Cheryl MacDiarmid has over 30 years' experience in the global pharmaceutical sector, notably with GSK, ViiV Healthcare and currently as a Non-Executive Director of AIM-listed Allergy Therapeutics. Cheryl is an internationally recognised opinion leader in the development & commercialisation of medicines. Trained as a pharmacist, she has held numerous senior leadership positions in the UK, EU, US and Canada, with responsibilities including global commercial strategy, P&L, sales, marketing, operations and Board membership. Cheryl is passionate about bringing new therapies to the right patients who can benefit. Jordan Clark is Chief Data Officer at Diaceutics. Jordan spearheads Diaceutics' comprehensive data strategy, spanning acquisition engineering and data science, to deliver cutting-edge analytics to clients and laboratories. With over a decade of experience at Diaceutics, he has cultivated a profound understanding of the critical role real-world data plays in optimising precision medicine. Jordan's academic and professional credentials in biomedical and clinical sciences, coupled with his state licensure as a haematology scientist, underscore his expertise. Additionally, Jordan is renowned for proficiency testing, bioinformatics and biomarker testing, honed through his involvement with UK NEQAS.
Reported Earnings • Sep 23First half 2024 earnings released: UK£0.031 loss per share (vs UK£0.018 loss in 1H 2023)First half 2024 results: UK£0.031 loss per share (further deteriorated from UK£0.018 loss in 1H 2023). Revenue: UK£12.3m (up 24% from 1H 2023). Net loss: UK£2.58m (loss widened 74% from 1H 2023). Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 87 percentage points per year, which is a significant difference in performance.
お知らせ • Sep 09Diaceutics PLC to Report Q2, 2024 Results on Sep 17, 2024Diaceutics PLC announced that they will report Q2, 2024 results on Sep 17, 2024
お知らせ • Aug 27Diaceutics PLC Launches Enhanced Rare-Disease OfferingDiaceutics PLC announced a significant enhancement to its offering which has facilitated a new rare-disease contract win. Access to this new data will revolutionise the early identification of patients, a crucial growth area for pharma companies developing therapies for rare-diseases. Leveraging data utilisation, it will improve earlier patient diagnosis and ultimately, clinical outcomes. Driving this enhancement are 3 key developments within the Diaceutics business as follows: Onboarding of New Data Partners:A number of new rare-disease genomic lab data partners have joined the DXRX network. These partners specialise in genetic testing, including the recognised testing lab in the United States for genetically acquired rare diseases. Advanced Lab Labelling Natural Language Processing (NLP):Diaceutics has updated its advanced lab labelling NLP process to standardise and add value to the new data. This process enables complex labelling such as pathogenic vs Variants of Unknown Significance (VUS) variant calling which until now has proven challenging for the industry to identify. Access to Additional Industry Experts:The company now has a team of industry experts with deep rare-disease experience to support biopharma business opportunities and ensure clients derive maximum value from Diaceutics' deep-data offering. Despite medical and scientific advances, diagnosing rare diseases remains a significant challenge for biopharma companies. Many patients face years of multiple referrals, inconclusive test results and limited treatment benefits. Early diagnosis and quick interventions are crucial for patient survival and quality of life. A precision medicine approach can end these diagnostic odysseys and open opportunities for better clinical outcomes for patients in need. The strategic enhancements announced will enable Diaceutics to identify more patients earlier and in doing so, help pharma customers to better commercialise gene therapies for rare diseases. Leveraging these business enhancements, Diaceutics has already secured a new contract to provide a multi-product solution to support the commercialisation of a therapy in a rare autosomal-recessive disease. This initial contract win demonstrates Diaceutics' ability to meet the complex needs of this market.
お知らせ • Aug 19Diaceutics PLC Announces Launch of PMxDiaceutics announced it has launched PMx, a suite of data-driven services built for the promotion and commercialisation of precision medicines and that it has reached agreement with a leading biotech to become its primary promotional partner for the launch of a breakthrough oncology precision medicine in the US using PMx. This partnership represents Diaceutics' seventh enterprise-wide engagement, and the first PMx primary promotional partnership deal whereby Diaceutics' fee structure is aligned with patient recruitment onto therapy. PMx unlocks new revenue streams for Diaceutics and shows the path to considerable increase in revenue per brand. Terms of the Agreement: Under the terms of the agreement, Diaceutics will leverage its DxRx platform, specifically its best-in-class genomic lab data, lab network, omni-channel, digital and peer to peer physician education to enable drug commercialisation. Diaceutics' partner will retain all rights to the license for the drug. This agreement is to deploy PMx through to the end of 2025 and is worth at least £2.4 million in service revenue to Diaceutics, with additional milestone fees estimated to be worth another £1.9 million payable during that period based on successful patient recruitment onto therapy. There is an expectation that the agreement will extend beyond 2025 should the initial phase be successful.
お知らせ • Jul 23Diaceutics plc Announces Board ChangesDiaceutics PLC announces the following changes to its board. Deborah Davis has informed the board after three and a half years' service as Non-Executive Chair of Diaceutics, of her intention to step down from the board effective 1 October 2024. Peter Keeling, a co-founder and Executive Director of Diaceutics will succeed Deborah as Non-Executive Chair effective 1 October 2024. Peter will also serve as a Non-Executive Director on the Remuneration and Audit & Risk Committees.
Recent Insider Transactions • May 26Independent Non-Executive Director recently bought €60k worth of stockOn the 22nd of May, Graham Paterson bought around 40k shares on-market at roughly €1.51 per share. This transaction increased Graham's direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €123k more in shares than they have sold in the last 12 months.
Reported Earnings • May 22Full year 2023 earnings releasedFull year 2023 results: Revenue: UK£23.7m (up 22% from FY 2022). Net loss: UK£1.75m (down 341% from profit in FY 2022). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
お知らせ • Mar 21Diaceutics PLC Launches Significant Upgrade to Its DXRX PlatformDiaceutics PLC has launched a significant upgrade to its DXRX platform, including industry and technologically leading de-identification, generative AI (Diaceutics Large Lab Model, DLLM) and new comprehensive US data sets that include data on social determinants of health. Not only does the upgrade increase the power and efficiency of the platform, but also the applicability of Diaceutics' subscription services into new parts of the precision medicine lifecycle, expanding the Company's addressable market. This new functionality enables the DXRX platform to breakdown siloed datasets and provide greater depth and breadth of Diaceutics' longitudinal insight of the patient journey, at increased speed and scale. As a result of the upgrade, multiple stakeholders within the life sciences industry can now access a best in class, real world data set that is HIPAA compliant, at a pace that previously would not have been possible, helping to address healthcare inequalities and enable more patients to access appropriate therapies.
お知らせ • Jan 19+ 1 more updateDiaceutics PLC, Annual General Meeting, Jun 24, 2024Diaceutics PLC, Annual General Meeting, Jun 24, 2024.
New Risk • Oct 10New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €92.7m (US$98.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (0.03% net profit margin). Market cap is less than US$100m (€92.7m market cap, or US$98.0m).
Board Change • Oct 05Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Chair Llewelyn Davis was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Sep 28First half 2023 earnings released: UK£0.018 loss per share (vs UK£0.009 loss in 1H 2022)First half 2023 results: UK£0.018 loss per share (further deteriorated from UK£0.009 loss in 1H 2022). Revenue: UK£9.92m (up 32% from 1H 2022). Net loss: UK£1.49m (loss widened 94% from 1H 2022). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 50 percentage points per year, which is a significant difference in performance.
New Risk • Sep 27New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 0.03% Last year net profit margin: 0.8% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. This is currently the only risk that has been identified for the company.
お知らせ • Sep 27Diaceutics Announces Executive ChangesDiaceutics announced the founder and chief executive of the company is stepping down after nearly two decades at the helm. Peter Keeling co-founded the company in 2005, growing it from a small consulting service provider to a listed company which employs 161 people across Europe and North America. He will step down as chief executive in January, with chief information officer Ryan Keeling becoming chief executive-designate with immediate effect. Ryan, who is Peter’s nephew, joined Diaceutics in 2006 and became a member of the board of directors following the company's listing on the AIM in 2019.
お知らせ • Sep 22Diaceutics PLC Announces Executive Changes, Effective 1 October 2023Diaceutics PLC announced the appointment of Graham Paterson as an independent Non-Executive Director of the company effective 1 October 2023. The Company also announced the retirement of Charles Hindson as a Non-Executive Director of Diaceutics PLC also effective 1 October 2023. Graham Paterson is a highly experienced business leader and Non-Executive Director. He is currently a Non-Executive Director of Invesco Perpetual UK Smaller Companies Investment Trust plc, Baillie Gifford US Growth Trust plc and Chairman of Mobeus Income and Growth 4 VCT plc.He has held senior executive roles in a number of companies including TopQ Software Ltd. and SL Capital Partners. Graham Paterson is a Chartered Accountant and a member of the Institute of Chartered Accountants of Scotland and holds an Honours degree in Economics and Management from the University of St. Andrews. On appointment, Graham Paterson will become Chair of the Audit and Remuneration Committees of Diaceutics PLC.
お知らせ • Aug 29Diaceutics plc Launches Daily Alerts for Dxrx PlatformDiaceutics PLC announced an important and innovative upgrade to its DXRX platformwhichsees the Company's DXRX Signal productnowproviding alerts on a daily basis. This ground-breaking innovation will provide Diaceutics' customers witheven more timely data to identifypatients who would benefit from their therapies and improve their commercial success. For patients, it means their chances of receiving the optimal therapy within the window of effectiveness is significantly improved. DXRX Signal utilizes real-world data collected from a diverse network of over ~500 labs, encompassing academic, community, and commercial facilities. This comprehensive data pool ensures supply chain reliability and encompasses both geographical and clinical diversity. For Diaceutics' customers, this translates into extensive coverage across a spectrum of medical conditions, including oncology, rare diseases, auto-immune disorders, cardiovascular and infectious diseases. DXRX Signal has identified over 46,000 patients so far in 2023 for its biopharma clients. Building upon the foundation of DXRX Signal, Diaceutics has introduced this pivotal enhancement. These alerts, now available on a daily basis, empower Diaceutics' customers with even timelier insights as they deploy products to pinpoint patients and elevate their commercial success. This innovation equips healthcare professionals with crucial data on a daily basis, and within days of a positive test result. With increased timely access to diagnostic information, physicians can be engaged precisely during the treatment decision window, ensuring the most effective drugs or therapies are offered promptly to patients.
お知らせ • Jul 25Diaceutics PLC to Report First Half, 2023 Results on Sep 26, 2023Diaceutics PLC announced that they will report first half, 2023 results on Sep 26, 2023
Reported Earnings • Apr 19Full year 2022 earnings released: EPS: UK£0.009 (vs UK£0.007 in FY 2021)Full year 2022 results: EPS: UK£0.009 (up from UK£0.007 in FY 2021). Revenue: UK£19.5m (up 40% from FY 2021). Net income: UK£724.0k (up 29% from FY 2021). Profit margin: 3.7% (down from 4.0% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.
お知らせ • Nov 01Diaceutics PLC Announces Release of Study into Inefficiencies Within Personalised Medicine and Its Impact on Cancer PatientsDiaceutics PLC announced the release of a large-scale study highlighting that a significant number of eligible patients treated for lung cancer did not receive access to the medicines most suitable to them, and therefore did not benefit from personalised medicine treatment. The study, carried out in conjunction with a broad stakeholder group across the Personalised Medicine Coalition, was made possible by the Diaceutics Data Repository, a database consisting of 600 million patient records available on the DXRX platform. The study examined de-identified Medicare claims and laboratory data from 38,068 US-based patients diagnosed with advanced non-small cell lung cancer in 2019 to identify the operational inefficiencies in the diagnosis and testing journey across this dataset. Overall, the publication identified that diagnostic testing-informed treatment strategies benefitted only 36% of the patients in the cohort. Of this group, 18% of patients did not receive the correct treatment as a result of inconclusive or false negative diagnostic results, and 29% of patients who had a successful diagnostic test were not prescribed the indicated treatment that they could have benefitted from. These findings represent the first step in understanding and pinpointing the nuances behind what prevents millions of people from getting the correct and timely healthcare they need. While the study was collected from US-based data, the findings are significant and reflective of the clinical gaps across other geographies and cancer types. For the pharmaceutical community, the study highlights the need for greater investment into those technologies and data repositories which facilitate the wider application of personalised medicines. It also provides the basis for better understanding the action required by these stakeholders to tackle these clinical gaps, and to track progress going forward. Diaceutics' Data Repository represents a world-leading diagnostic data set, combining multiple sources of information to build a complete picture of a typical patient's diagnostic journey. The mining capability of the DXRX platform allows the Company to identify Disease Diagnostic Pathways (DDPs) to determine the best possible testing journey for patients within a specific disease or disease area. The DDPs are both unique and proprietary to Diaceutics and are increasingly being developed for other therapeutic areas. As Diaceutics invests further in its platform, it will utilise access to the unrivalled wealth of data to continue removing testing hurdles and increasing patients' access to precision medicine.
Reported Earnings • Sep 28First half 2022 earnings released: UK£0.009 loss per share (vs UK£0.004 loss in 1H 2021)First half 2022 results: UK£0.009 loss per share (further deteriorated from UK£0.004 loss in 1H 2021). Revenue: UK£7.53m (up 26% from 1H 2021). Net loss: UK£767.0k (loss widened 129% from 1H 2021). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
お知らせ • Jul 26Diaceutics PLC to Report First Half, 2022 Results on Sep 27, 2022Diaceutics PLC announced that they will report first half, 2022 results on Sep 27, 2022
お知らせ • Jun 07Diaceutics PLC Announces New AI and ML Capabilities Enhance DXRX PlatformDiaceutics PLC has announced significant enhancements to its proprietary DXRX platform, improving the user experience. From within their DXRX dashboard, customers can now access three new AI-powered tools, helping to ensure their medicines get to patients quicker. They are Smart Trend Analysis, Next Best Step and Event Alerts. Smart Trend Analysis:provides automated analysis of key trends and changes within customer data to uncover hidden insights including the production of bespoke, meaningful commentary for use in reports, with the customer able to customise the reports to focus on the datasets important to them. Next Best Step:provides automated identification as to where in the ecosystem customers should target their diagnostics investments in order to get patients tested and treated faster. Event Alerts:deliver just in time email notifications on significant changes within the data, such as if a new lab has started to offer diagnostic testing. These services are highly sought-after by Diaceutics customers and previously relied on the expertise of the Diaceutics' data analysis team or availability of the customers' own data science resource. Now produced automatically,customer queries can be answered more comprehensively and faster than ever before. This increased functionality represents a significant step in Diaceutics' strategy to embed its platform within its customers' own digital systems and day-to-day commercial processes.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. CFO & Director Nick Roberts was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Recent Insider Transactions • Apr 10Executive Officer recently sold €237k worth of stockOn the 6th of April, Philip White sold around 200k shares on-market at roughly €1.19 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €464k more than they bought in the last 12 months.
お知らせ • Dec 09Diaceutics PLC Announces Test Signal Launch and Contract WinsDiaceutics PLC announced the launch of its real-time Test Signal service in the US. Test Signal alerts a pharma customer when a patient tests positive for a biomarker linked to the profile of therapeutic linked to the pharmaceutical company. This information can now be provided within days of the test result being recorded by laboratories linked to this new service. Test Signal allows the opportunity for real time identification of patients eligible for treatment and follow up by the pharmaceutical company's marketing organisation. This will allow quicker and better support to biomarker testing, allowing earlier treatment with the most appropriate drug treatment sooner. Test Signal was previously available as a monthly report. However, with the additional investment Diaceutics' has made, Test Signal alert is now available as a real time report further enhancing the DXRX Diaceutics Commercialisation Platform. This service now adds to the comprehensive suite of modules now being offered by Diaceutics, on a subscription basis. Work is now nearing completion for additional modules that will join Test Signal on the DXRX Commercialisation Platform. Test Signal was trialled prior to launch with key Pharma clients from the beginning of November 2021 and the Company is delighted to report that it has already secured six multiyear data subscriptions for the service. This opens up a new revenue stream for Diaceutics which will be added to as the Commercialisation Platform matures, underpinning the Company's confidence in achieving sustained long-term growth.
Reported Earnings • Sep 16First half 2021 earnings released: UK£0.004 loss per share (vs UK£0.015 profit in 1H 2020)The company reported a soft first half result with weaker earnings and weaker control over costs, although revenues improved. First half 2021 results: Revenue: UK£5.97m (up 13% from 1H 2020). Net loss: UK£335.0k (down 131% from profit in 1H 2020).
お知らせ • Sep 15Diaceutics PLC Provides Earnings Guidance for the Year 2021Diaceutics PLC provided earnings guidance for the year 2021. This shift in the trend of seasonality is reflected in revenue result reported for first half of 2021 which represents 44% of the external revenue expectations for the 2021 financial year (H1 2020: 41% of total revenue for the 2020 financial year).
Recent Insider Transactions • May 14Chief Commercial Officer recently sold €73k worth of stockOn the 12th of May, Jordan Clark sold around 50k shares on-market at roughly €1.45 per share. In the last 3 months, there was an even bigger sale from another insider worth €284k. Insiders have been net sellers, collectively disposing of €357k more than they bought in the last 12 months.
Recent Insider Transactions • May 07CFO & Executive Director recently sold €284k worth of stockOn the 4th of May, Philip White sold around 200k shares on-market at roughly €1.42 per share. This was the largest sale by an insider in the last 3 months. This was Philip's only on-market trade for the last 12 months.
Reported Earnings • Mar 16Full year 2020 earnings releasedThe company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: UK£12.7m (down 5.6% from FY 2019). Net income: UK£263.0k (down 34% from FY 2019). Profit margin: 2.1% (down from 3.0% in FY 2019).
お知らせ • Mar 05Diaceutics PLC Appoints Nikita Lynn as Vice President of FinanceDiaceutics PLC announced the appointment of Nikita Lynn as Vice President of Finance. Nikita has been promoted to this role following her tenure as Senior Director of Corporate Advancement. In her new role within Diaceutics, Nikita will be responsible for the financial operations and corporate development of the Company, reporting to the CFO, Board of Directors and Non-Executive Directors. She brings extensive experience in financial reporting, taxation and auditing for public companies to the position.
Valuation Update With 7 Day Price Move • Jan 12Investor sentiment improved over the past weekAfter last week's 18% share price gain to UK£1.89, the stock is trading at a trailing P/E ratio of 32.5x, up from the previous P/E ratio of 27.6x. This compares to an average P/E of 60x in the Life Sciences industry in Europe. Total returns to shareholders over the past year are 45%.
お知らせ • Jan 11Diaceutics PLC to Report Fiscal Year 2020 Results on Mar 15, 2021Diaceutics PLC announced that they will report fiscal year 2020 results on Mar 15, 2021
Valuation Update With 7 Day Price Move • Dec 28Investor sentiment improved over the past weekAfter last week's 141% share price gain to UK£3.50, the stock is trading at a trailing P/E ratio of 24.9x, up from the previous P/E ratio of 10.3x. This compares to an average P/E of 59x in the Life Sciences industry in Europe. Total returns to shareholders over the past year are 198%.
お知らせ • Dec 23+ 1 more updateDiaceutics PLC Announces the Resignation of Julie Goonewardene as Non-Executive Chair, with Effect from December 31, 2020Diaceutics PLC announced the resignation of Julie Goonewardene as Non-Executive Chair. Julie will step down on December 31, 2020. Having been with Diaceutics for almost 10 years Julie has, with the support of the Board, decided to step down.
お知らせ • Dec 02Diaceutics and Alva10 Partner to Deliver Value-Based Test Reimbursement Model for US Payers, Pharma and Testing Providers Via Dxrx PlatformDiaceutics PLC announced a new partnership with Alva10 to address test coverage and reimbursement challenges in precision medicine diagnostics. The partnership will leverage Diaceutics’ newly-launched platform DXRX – The Diagnostic Network to facilitate collaboration between pharma, health insurance and government payers, labs and diagnostic companies earlier in the test development process and deliver enhanced coverage and reimbursement support for biomarker testing to improve patient outcomes. The partnership sees Alva10 join the DXRX global network of leading providers in precision medicine diagnostics in 51 countries including the areas of test standardization, access and reimbursement, quality assessment, laboratory training, technical support and education, all with the shared vision of enabling the seamless delivery of diagnostic testing for precision medicines. Alva10 works with payers and physicians to identify areas of inefficient spend, where coverage of diagnostic tools can improve patient outcomes and payer economics. Through the company’s proprietary model M.A.T.E.TM, Alva10 restructures the relationship between health insurance payers and precision medicine diagnostic companies to increase utilization and compliance. This enables optimal use of diagnostic tools to improve diagnosis of disease, determine drug response, and identify adverse events. Diaceutics’ partnership with Alva10 on its DXRX platform addresses the need for a better test reimbursement model in the US, to enable collaboration earlier in the development process, so that test developers and providers are adequately resourced to develop tests for new therapies coming to market. In today’s system, the most common practice for test reimbursement involves a laboratory or diagnostic company developing the test, followed by a process to prove clinical utility and cost-effectiveness of the test. The end goal is to gain coverage and reimbursement at a level that enables market success for the test’s associated therapy.
お知らせ • Oct 29Diaceutics PLC Launches Diagnostic Network for Precision Medicine to Solve Global Cancer Testing IssuesDiaceutics PLC announced the launch of DXRX – The Diagnostic Network which has been designed to accelerate the end-to-end development and commercialization of precision medicine diagnostics by reducing time to peak biomarker test adoption for cancer testing from years to months. As a solution to today’s broken testing ecosystem, DXRX brings together stakeholders from across the industry to collaborate in a vibrant marketplace to solve real-world testing issues in a secure, standardized way for patients. DXRX integrates a pipeline of global diagnostic testing data into one secure platform providing access to transparent, real-time reporting on diagnostic utilization at a local level across multiple therapeutic areas. Early collaborations between pharma, labs and diagnostic companies are live on the platform’s marketplace with 38 Laboratories and Diagnostic Companies onboarded from across EU, Asia and the US. These collaborations are designed to improve test standardization, reimbursement, regulatory support and External Quality Assessment (EQA). Collaborators include Synlab, PathGroup (US), SRL Diagnostics (Asia), Fundación Jimenez Díaz, The Royal Marsden NHS Foundation Trust, Istituto Nazionale Tumori Regina Elena Roma and Diatech Pharmacogenetics (EU). Two global pharmaceutical clients are also piloting the technology. The platform enables pharma clients to monitor and enhance test quality at local level to increase return on investment across multiple brands, and leverage a broad network of local partnership opportunities to implement best-in-class testing for their precision medicine portfolios. DXRX also enables clients to outsource the end-to-end diagnostic development and commercialization process from biomarker discovery to in-market test availability in order to reduce time to market for new therapies. Furthermore, DXRX also provides users access to a global expert advisory panel of key opinion leaders from the areas of oncology, including lung cancer research and colorectal research; pathology, including tissue pathology and uropathology; molecular diagnostics; digital image analysis; telemedicine and informatics; external quality assessment (EQA); and FDA-expertise.
Valuation Update With 7 Day Price Move • Oct 29Market pulls back on stock over the past weekAfter last week's 28% share price decline to UK£1.38, the stock is trading at a trailing P/E ratio of 27.1x, down from the previous P/E ratio of 37.9x. This compares to an average P/E of 60x in the Life Sciences industry in Europe. Total returns to shareholders over the past year are 24%.
お知らせ • Oct 05Diaceutics PLC Partners with Global EQA Providers to Implement Best-In-Class Testing StandardsDiaceutics PLC announces three new partnerships on its DXRX platform, as it continues with its mission to get every patient the treatment they deserve. The company has signed agreements with external quality assessment (EQA) organizations Canadian Pathology Quality Assurance – Assurance Qualité Canadienne en Pathologie (CPQA-AQCP), European Molecular Genetics Quality Network (EMQN CIC) and Nordic Immunohistochemical Quality Control (NordiQC). The partnerships will help to establish best-in-class global laboratory standards for diagnostic testing through in-lab quality assurance and will provide the transparency which pharmaceutical companies need to reach more patients with their precision medicines. By partnering with CPQA-AQCP, EMQN CIC and NordiQC on DXRX – the world’s first diagnostic network for precision medicine – Diaceutics will support the implementation of accurate and high-quality testing across its 2500+ laboratory relationships. These collaborations facilitate a critical piece of the end-to-end solution which DXRX enables for the development and commercialization of precision medicine diagnostics. They are also part of multiple partnerships which Diaceutics is building with industry providers across the globe to help achieve their mission of getting every patient the treatment they deserve. Currently focused on the Canadian market, CPQA-AQCP is dedicated to monitoring and improving the proficiency of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) testing. DXRX is a global platform which will enable CPQA-AQCP to expand its services further worldwide. The organization is currently collaborating with Diaceutics on a project sponsoring the HER2 biomarker modules for gastric cancer. Using IHC and FISH, they are assessing the landscape and efficiency of HER2 gastric cancer testing, which has now been on the market for more than 10 years. EMQN CIC provides molecular genetics, molecular pathology, and technique-specific EQA schemes for the global molecular testing market. It is currently collaborating with Diaceutics on a pilot study involving mutations in the EGFR, PIK3CA, KRAS, HRAS, NRAS, KIT, TP53 and BRAF genes, which will help laboratories using high throughput technologies – such as NGS – to accurately validate assay sensitivity and specificity.
お知らせ • Aug 27Diaceutics PLC announced that it has received £4 million in funding from SVB Silicon Valley Bank, Investment ArmDiaceutics PLC (AIM:DXRX) announced that it has received £4 million in a round of funding from returning invetsor SVB Silicon Valley Bank, Investment Arm on August 26, 2020.
